Hanneke M. Straaten

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

Marijke R. Canninga‐van Dijk, Hanneke M. Straaten, Rob Fijnheer et al. · Blood · 2004 · 129 citations · Full text

Life Sciences, Clinical Sciences, Immunology +12

Pulmonary complications after T-cell-depleted allogeneic stem cell transplantation: low incidence and strong association with acute graft-versus-host disease

C. Huisman, Hanneke M. Straaten, Marijke R. Canninga‐van Dijk et al. · Bone Marrow Transplantation · 2006 · 46 citations · Full text

Medicine, Hematology, Immunology +16

Extra-Domain-A Fibronectin: A New Marker of Fibrosis in Cutaneous Graft-Versus-Host Disease

Hanneke M. Straaten, Marijke R. Canninga‐van Dijk, Leo F. Verdonck et al. · Journal of Investigative Dermatology · 2004 · 35 citations · Full text

Medicine, Pathobiology, Pathology +16

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Sabina Kersting, Julie Dubois, Kazem Nasserinejad et al. · The Lancet Haematology · 2022 · 31 citations · Full text

Medicine, Hematology, Pharmacology +3

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Lina van der Straten, Claudia A.M. Stege, Sabina Kersting et al. · Blood · 2023 · 28 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +6